Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Manages secondary hyperparathyroidism and resultant metabolic bone disease. Sold as Rocaltrol, Calcijex, Vectical. Every FDA application for this active ingredient: 4 branded and 19 generic.
As of Nov 15, 2026, FDA lists 23 applications for Calcitriol (sold as Rocaltrol, Calcijex, Vectical), first approved Aug 17, 1978, with 6 new uses approved and 0 published complete response letters.
First approved: Aug 17, 1978
Applications: 23
New uses approved: 6
Complete response letters: 0
Medicare spending, 2025: $27.8M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Calcitriol
Part D
$27.8M
+5%
347,443
Vectical
Part D
$69K
-93%
44
Rocaltrol
Part D
$4K
-79%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
CALCITRIOL 0.25 MCG CAPSULE: $0.151 per unitGeneric · -9% in a year
CALCITRIOL 0.5 MCG CAPSULE: $0.230 per unitGeneric · -4% in a year
CALCITRIOL 1 MCG/ML SOLUTION: $6.22 per MLGeneric · -2% in a year
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Abbvie
Teva
Fresenius Kabi USA
Hikma